{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T10:21:30Z","timestamp":1791195690972,"version":"4.1.0"},"reference-count":49,"publisher":"Society of Nuclear Medicine","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.2967\/jnumed.122.264979","type":"journal-article","created":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T15:15:20Z","timestamp":1683213320000},"page":"1062-1068","source":"Crossref","is-referenced-by-count":24,"title":["Evaluation of Candidate Theranostics for<sup>227<\/sup>Th\/<sup>89<\/sup>Zr Paired Radioimmunotherapy of Lymphoma"],"prefix":"10.2967","volume":"64","author":[{"given":"Diane S.","family":"Abou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Longtine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Fears","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Benabdallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Unnerstall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyuhwan","family":"Shim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abbie","family":"Hasson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanwen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Ulmert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Floriane","family":"Mangin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serife","family":"Ozen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Raibaut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Brand\u00e8s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Claude","family":"Chambron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Tatum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren","family":"Magda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard L.","family":"Wahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel L.J.","family":"Thorek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2023,5,4]]},"reference":[{"key":"2023063006250744000_64.7.1062.1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-0298"},{"key":"2023063006250744000_64.7.1062.2","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1053\/j.semnuclmed.2020.02.003","article-title":"Supply and clinical application of actinium-225 and bismuth-213","volume":"50","author":"Morgenstern","year":"2020","journal-title":"Semin Nucl Med."},{"key":"2023063006250744000_64.7.1062.3","doi-asserted-by":"crossref","first-page":"6946","DOI":"10.7150\/thno.38236","article-title":"Preclinical evaluation of an 111In\/225Ac theranostic targeting transformed MUC1 for triple negative breast cancer","volume":"10","author":"Kelly","year":"2020","journal-title":"Theranostics."},{"key":"2023063006250744000_64.7.1062.4","doi-asserted-by":"crossref","first-page":"4807","DOI":"10.1021\/acs.molpharmaceut.9b00542","article-title":"111In- and 225Ac-labeled cixutumumab for imaging and \u03b1-particle radiotherapy of IGF-1R positive triple-negative breast cancer","volume":"16","author":"Solomon","year":"2019","journal-title":"Mol Pharm."},{"key":"2023063006250744000_64.7.1062.5","doi-asserted-by":"publisher","DOI":"10.1097\/HP.0b013e3181e28cdb"},{"key":"2023063006250744000_64.7.1062.6","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1521"},{"key":"2023063006250744000_64.7.1062.7","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-3614"},{"key":"2023063006250744000_64.7.1062.8","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.263079"},{"key":"2023063006250744000_64.7.1062.9","first-page":"316","article-title":"In vitro and in\u00a0vivo comparison of 3,2-HOPO versus deferoxamine-based chelation of zirconium-89 to the antimesothelin antibody anetumab","volume":"36","author":"Roy","year":"2021","journal-title":"Cancer Biother Radiopharm."},{"key":"2023063006250744000_64.7.1062.10","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.262562"},{"key":"2023063006250744000_64.7.1062.11","doi-asserted-by":"publisher","DOI":"10.1107\/S0567739476001551"},{"key":"2023063006250744000_64.7.1062.12","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-011-2001-z"},{"key":"2023063006250744000_64.7.1062.13","doi-asserted-by":"crossref","first-page":"638","DOI":"10.3390\/molecules23030638","article-title":"Recent advances in zirconium-89 chelator development","volume":"23","author":"Bhatt","year":"2018","journal-title":"Molecules."},{"key":"2023063006250744000_64.7.1062.14","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.22771"},{"key":"2023063006250744000_64.7.1062.15","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.2967\/jnumed.117.203299","article-title":"Evaluation of next-generation anti-CD20 antibodies labeled with 89Zr in human lymphoma xenografts","volume":"59","author":"Yoon","year":"2018","journal-title":"J Nucl Med."},{"key":"2023063006250744000_64.7.1062.16","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1016\/j.tet.2011.01.073","article-title":"A new approach to cyclic hydroxamic acids: intramolecular cyclization of N-benzyloxy carbamates with carbon nucleophiles","volume":"67","author":"Liu","year":"2011","journal-title":"Tetrahedron."},{"key":"2023063006250744000_64.7.1062.17","doi-asserted-by":"crossref","first-page":"4466","DOI":"10.3390\/cancers13174466","article-title":"The race for hydroxamate-based zirconium-89 chelators","volume":"13","author":"Feiner","year":"2021","journal-title":"Cancers (Basel)."},{"key":"2023063006250744000_64.7.1062.18","doi-asserted-by":"crossref","first-page":"4850","DOI":"10.1021\/ol201930e","article-title":"Palladium-catalyzed alkylation of ortho-C(sp2)-H bonds of benzylamide substrates with alkyl halides","volume":"13","author":"Zhao","year":"2011","journal-title":"Org Lett."},{"key":"2023063006250744000_64.7.1062.19","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1007\/s00259-016-3499-x","article-title":"Comparison of the octadentate bifunctional chelator DFO*-pPhe-NCS and the clinically used hexadentate bifunctional chelator DFO-pPhe-NCS for 89Zr-immuno-PET","volume":"44","author":"Vugts","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2023063006250744000_64.7.1062.20","doi-asserted-by":"publisher","DOI":"10.1021\/jm9016703"},{"key":"2023063006250744000_64.7.1062.21","doi-asserted-by":"publisher","DOI":"10.1016\/S0969-8043(02)00167-7"},{"key":"2023063006250744000_64.7.1062.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.nucmedbio.2005.12.004"},{"key":"2023063006250744000_64.7.1062.23","doi-asserted-by":"publisher","DOI":"10.1016\/0022-1759(84)90435-6"},{"key":"2023063006250744000_64.7.1062.24","first-page":"423","article-title":"The solution of a system of differential equations occurring in the theory of radioactive transformations","volume":"15","author":"Bateman","year":"1910","journal-title":"Proc Camb Philos Soc."},{"key":"2023063006250744000_64.7.1062.25","first-page":"455","article-title":"Performance evaluation of the microPET focus: a third-generation microPET scanner dedicated to animal imaging","volume":"46","author":"Tai","year":"2005","journal-title":"J Nucl Med."},{"key":"2023063006250744000_64.7.1062.26","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-01-066803"},{"key":"2023063006250744000_64.7.1062.27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nucmedbio.2018.05.003","article-title":"The impact of age on radium-223 distribution and an evaluation of molecular imaging surrogates","volume":"62-63","author":"Jiang","year":"2018","journal-title":"Nucl Med Biol."},{"key":"2023063006250744000_64.7.1062.28","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13550-017-0339-3","article-title":"IDAC-Dose 2.1, an internal dosimetry program for diagnostic nuclear medicine based on the ICRP adult reference voxel phantoms","volume":"7","author":"Andersson","year":"2017","journal-title":"EJNMMI Res."},{"key":"2023063006250744000_64.7.1062.29","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1093\/oxfordjournals.rpd.a006306","article-title":"Developments in the internal dosimetry of radiopharmaceuticals","volume":"105","author":"Stabin","year":"2003","journal-title":"Radiat Prot Dosimetry."},{"key":"2023063006250744000_64.7.1062.30","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.108.058651"},{"key":"2023063006250744000_64.7.1062.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.nucmedbio.2010.12.011"},{"key":"2023063006250744000_64.7.1062.32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0027508"},{"key":"2023063006250744000_64.7.1062.33","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.261016"},{"key":"2023063006250744000_64.7.1062.34","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1039\/D0SC06867E","article-title":"Towards the stable chelation of radium for biomedical applications with an 18-membered macrocyclic ligand","volume":"12","author":"Abou","year":"2021","journal-title":"Chem Sci."},{"key":"2023063006250744000_64.7.1062.35","first-page":"497","article-title":"Advances in precision oncology: targeted thorium-227 conjugates as a new modality in targeted alpha therapy","volume":"35","author":"Hagemann","year":"2020","journal-title":"Cancer Biother Radiopharm."},{"key":"2023063006250744000_64.7.1062.36","first-page":"672","article-title":"227Th-labeled anti-CD22 antibody (BAY 1862864) in relapsed\/refractory CD22-positive non-Hodgkin lymphoma: a first-in-human, phase I study","volume":"36","author":"Lind\u00e9n","year":"2021","journal-title":"Cancer Biother Radiopharm."},{"key":"2023063006250744000_64.7.1062.37","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1002\/jlcr.3875","article-title":"Thorium chelators for targeted alpha therapy: rapid chelation of thorium-226","volume":"63","author":"Ferrier","year":"2020","journal-title":"J Labelled Comp Radiopharm."},{"key":"2023063006250744000_64.7.1062.38","doi-asserted-by":"crossref","first-page":"8253","DOI":"10.1021\/acs.inorgchem.9b00736","article-title":"Synthesis and crystallographic characterization of the tetravalent actinide-DOTA complexes [AnIV(\u03ba8-DOTA)(DMSO)] (an = Th, U)","volume":"58","author":"Kent","year":"2019","journal-title":"Inorg Chem."},{"key":"2023063006250744000_64.7.1062.39","first-page":"431","article-title":"Preparation of TH227-labeled radioimmunoconjugates, assessment of serum stability and antigen binding ability","volume":"22","author":"Larsen","year":"2007","journal-title":"Cancer Biother Radiopharm."},{"key":"2023063006250744000_64.7.1062.40","doi-asserted-by":"crossref","first-page":"7205","DOI":"10.1021\/ic9606439","article-title":"Complexation of thorium(IV) and uranium(IV) by a hexaacetic hexaaza macrocycle: kinetic and thermodynamic topomers of actinide chelates with a large cavity ligand","volume":"35","author":"Jacques","year":"1996","journal-title":"Inorg Chem."},{"key":"2023063006250744000_64.7.1062.41","doi-asserted-by":"publisher","DOI":"10.1021\/jm990141f"},{"key":"2023063006250744000_64.7.1062.42","doi-asserted-by":"publisher","DOI":"10.1089\/108497800414329"},{"key":"2023063006250744000_64.7.1062.43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0042345"},{"key":"2023063006250744000_64.7.1062.44","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1007\/s00259-019-04343-2","article-title":"Direct comparison of the in\u00a0vitro and in\u00a0vivo stability of DFO, DFO* and DFOcyclo* for 89Zr-immunoPET","volume":"46","author":"Raav\u00e9","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2023063006250744000_64.7.1062.45","doi-asserted-by":"crossref","first-page":"103571","DOI":"10.1016\/j.ebiom.2021.103571","article-title":"Novel theranostic agent for PET imaging and targeted radiopharmaceutical therapy of tumour-infiltrating immune cells in glioma","volume":"71","author":"Foster","year":"2021","journal-title":"EBioMedicine."},{"key":"2023063006250744000_64.7.1062.46","unstructured":"Tatum D Xu J Magda D Butlin N , inventors; Lumiphore Inc., assignee. Macrocyclic ligands with pendant chelating moieties and complexes thereof. U.S. patent 10239878B2. March 26, 2019."},{"key":"2023063006250744000_64.7.1062.47","first-page":"15","article-title":"Radiochemical quality control methods for radium-223 and thorium-227 radiotherapies","volume":"38","author":"Hasson","year":"2023","journal-title":"Cancer Biother Radiopharm."},{"key":"2023063006250744000_64.7.1062.48","doi-asserted-by":"crossref","unstructured":"Abou DS Rittenbach A Tomlinson RE . First whole-body three-dimensional tomographic imaging of alpha particle emitting radium-223. bioRxiv website. https:\/\/www.biorxiv.org\/content\/10.1101\/414649v1.full. Published September 26, 2018. Accessed March 23, 2023.","DOI":"10.1101\/414649"},{"key":"2023063006250744000_64.7.1062.49","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-16-0251"}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.122.264979","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T13:28:04Z","timestamp":1688131684000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.122.264979"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,4]]},"references-count":49,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,6,30]]},"published-print":{"date-parts":[[2023,7]]}},"alternative-id":["10.2967\/jnumed.122.264979"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.122.264979","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,4]]}}}